This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG.Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. PharmacoEconomics 25: 963-977, No. 11, 2007
About this article
Cite this article
Entecavir of benefit in HBeAg-positive Hep B. Pharmacoecon. Outcomes News 542, 9 (2007). https://doi.org/10.2165/00151234-200705420-00018
- Chronic Hepatitis
- Markov Model
- Medical Cost
- Cumulative Incidence